Navigation Links
Epi-Peel® Glycolic Peel System

ProductsEpi-Peel® Glycolic Peel System
Company Dermatologic Cosmetic Laboratories
Item Epi-Peel® Glycolic Peel System
Features 
  • Willowherb Extract, at a clinically active level, helps soothe and calm the skin while the beneficial effects of the 40% active glycolic peel are taking effect.
  • Controlled dose, concentration and timing provide reproducible & predictable results each and every time.
  • Easy 3-step system makes procedure more efficient than ever before.
  • Advanced level 1 (40% active) gel formulation provides easier, more even application.
  • Available in 2 levels: level 1 (40% active) with willowherb extract. level 2 (70% active) includes the most effective topical anti-oxidant, Vitamin C, in a highly stable water soluble form- magnesium ascorbyl phosphate. The addition of this ingredient helps even skin tone and maximize efficacy of the glycolic peel.
Description The Epi-Peel® System is available in two innovative formulations: Level 1 (40% active) and Level II (70% active). The Level I (40% active) formulation introduces a clinically active level of willowherb extract, which DCL scientists have identified and incorporated into the formula to help soothe and calm the skin while the beneficial effects of the peel are taking effect. The formula is also a gel-like consistency designed for easier spreadability and even application. The Level II (70% active) formulation includes the most effective topical anti-oxidant, Vitamin C, in a highly stable water soluble form- magnesium ascorbyl phosphate. The addition of this ingredient helps even skin tone and maximize efficacy of the glycolic peel.
Info Dermatologic Cosmetic Laboratories
Customer Service: 203-467-1570
Web site: http://www.dclskincare.com/

Related medicine products :

1. Glycolic Peels (Medical)
2. Glycolic Acid Peel
3. Silicone Oil Cannula System - 20 Gauge
4. Silicone Oil Cannula System - 19 Gauge
5. SuperVu Galilean System
6. KOWA nonmyd 7 / VK-2 Digital Imaging System
7. KOWA nonmyd a-D / VK-2 Digital Imaging System
8. Refraction System RT-2100
9. Odyssey Phacoemulsification System
10. SIStem Phacoemulsification System
11. Precisionist Phacoemulsification System
Super High Density, multi frequency Side Fire "T intraoperative transducer. A wide field of view is this transducers benefit. Change frequencies on the fly for deeper penetration or for superficial n
This is a 3D transducer for endovaginal imaging in OB/GYN.
Super High Density, 120 degree field of view, straight handle, multi-frequency, convex endovaginal transducer.
Prostate biopsy transducer.
Medicine Products:
(Date:12/3/2008)..., HeadNorth Foundation has pledged $975,000 to Bu...support cutting-edge stem cell research. The fundi... Project, will support efforts by Dr. Evan Snyder,...k Tuszynski, Director, Center for Neural Repair at...tem cells to treat chronic spinal cord injuries. ,...
(Date:12/3/2008)..., A new study has found that a school-based asthm...fornia school district was shown to reduce symptom...o suffered from asthma were able to go to school. ...rnal of School Health . , Nearly 10% or 6.8 mill... the Centers for Disease Control and Prevention. T...
(Date:12/3/2008)... DALLAS, Dec. 3 BeaconEquity.com a...s making news today. , , Investors can vie...ing: http://www.BeaconEquity.com/m , , To...NYSE: SPC ), Williams-Sonoma Inc. (NYSE: WSM )...ght Express Corp. (NYSE: WXS ), Morgans Hotel Gr...
(Date:12/3/2008)... SAN FRANCISCO, Dec. 3 Canadian te... the brain health revolution on Thursday night whe... airs on the Canadian Broadcast,Corporation net...ame by,author Norman Doidge, MD, the documentary ...sticity and features the science, scientists, prod...
Breaking Medicine News(10 mins):Health News:Burnham and HeadNorth Foundation join forces to advance spinal cord research 2Health News:Study shows school-based program enables children and adolescents to better manage chronic disease 2Health News:Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: SPC, WSM, MRX, WXS, MHGC, DSPG 2Health News:Posit Science Featured in Canadian Documentary on the Brain 2
...roke in the Indian capital taking the toll since S... across north India. 'At least three people died... All the three were men and two of them apparently...' said Dinesh, in charge of the DDU police chowki....
...miserable, it drags you to worse ills in the futu...hers from Rush University Medical Center in Chicag...epressed are 40 times more likely to develop mild ...loss that is often a transitional stage between no...
...t healthcare systems in India has received a sever... chikungunya viral fever in the state. Last year... the mosquito-borne viral fever in the coastal dis...llam and Ernakulam. The present outbreak, which h...
...ne for cholera that can be well, eaten. Immunol...d his colleagues inserted the genetic material fro...xin, into a rice plant, whose genome has recently ...oxin and when the rice grains were fed to mice the...
Other Medicine News:Health News:Stress- Harms Now And Later 2Health News:Chikungunya Affects Kerala's Healthcare Status 2Health News:Vaccines On Your Plate 2
(Date:12/2/2008)...LA JOLLA, Calif., Dec. 2 TorreyPin...unced positive results from a 26 patient Phase II ...ent for xerostomia, or dry mouth, in patients with...int of a statistically significant increase in sal...hree doses: 10 mg, 15 mg, and 20 mg. These doses w...
(Date:12/1/2008)... , , , CHICAGO, Dec. 2 /PRNewswire-USNe...n mammography (PEM), a new technique for imaging t...y or a woman,s hormonal status, two factors that l... MRI at detecting cancer. Results will be presente...Society of North America (RSNA). , , "The ...
(Date:12/1/2008)...INDIANAPOLIS, Dec. 1 Roche announc...aluate differences in perceived pain and,discomfo...CU-CHEK blood,glucose monitoring systems and lanc...sults indicated that, overall, the ACCU-CHEK Aviva...ing systems and the ACCU-CHEK Multiclix, ACCU-CHEK...
(Date:12/1/2008)...PLYMOUTH MEETING, Pa., Dec. 1 /PRNewswire-FirstCal... announced that dosing of subjects has begun in st...ing dose Phase 1b study of trodusquemine (MSI-1436...36 is a novel therapeutic for the treatment of typ... peripherally to regulate insulin and leptin pathw...
Breaking Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Use of PressureWire 28R 29 Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature Two New Studies Report 1611 1Use of PressureWire 28R 29 Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature Two New Studies Report 1611 2Use of PressureWire 28R 29 Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature Two New Studies Report 1611 3Actor Greg Grunberg Meets With the Epilepsy Advocates in Washington DC 15380 1Actavis Receives Approval of Generic Wellbutrin SR 28R 29 and Zyban 28R 29 Tablets in the U S 4241 1Actavis Receives Approval of Generic Wellbutrin SR 28R 29 and Zyban 28R 29 Tablets in the U S 4241 2Pharsight Invited to Present on HIV Modeling and Simulation at ASCPT Annual Meeting 1610 1Pharsight Invited to Present on HIV Modeling and Simulation at ASCPT Annual Meeting 1610 2Pharsight Invited to Present on HIV Modeling and Simulation at ASCPT Annual Meeting 1610 3
...S WIRE)--Jul 9, 2007 - TransPharma Medical,Ltd., a...evelopment,and commercialization of drug products ...livery technology, announced today,promising resul...e,safety and pharmacokinetic profile of its ViaDer...rosis., A seven day, repeated dose application, pa...
...E)--Jul 8, 2007 - Late-breaking Phase III,clinical...al,Society on Thrombosis and Haemostasis (ISTH) Co...ieved superior efficacy in the,prevention of venou...e replacement surgery in a head-to-head comparison...tients in the RECORD3,(REgulation of Coagulation i...
Other Medicine Technology:TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 2TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5